Back to Search
Start Over
Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Renal Dysfunction
- Source :
- Racionalʹnaâ Farmakoterapiâ v Kardiologii, Vol 17, Iss 1, Pp 62-72 (2021)
- Publication Year :
- 2021
- Publisher :
- Stolichnaya Izdatelskaya Kompaniyaizdat, 2021.
-
Abstract
- Atrial fibrillation and renal dysfunction often coexist, each disorder may predispose to the other and contribute to worsening prognosis. Both atrial fibrillation and chronic kidney disease are associated with increased risk of stroke and thromboembolic complications. Oral anticoagulation for stroke prevention is therefore recommended in patients with atrial fibrillation and decreased renal function. Each direct oral anticoagulant has unique pharmacologic properties of which clinician should be aware to optimally manage patients. The doses of direct oral anticoagulants require adjustment for renal function. There is debate regarding which equation, the Chronic Kidney Disease Epidemiology (CKD-EPI) equation vs. the Cockcroft-Gault equation, should be used to estimate glomerular filtration rate in patients with atrial fibrillation treated with direct oral anticoagulants. Our review tries to find arguments for benefit of direct oral anticoagulants in patients with renal dysfunction.
- Subjects :
- medicine.medical_specialty
apixaban
Renal function
RM1-950
urologic and male genital diseases
Amiodarone
Dabigatran
Internal medicine
medicine
Diseases of the circulatory (Cardiovascular) system
atrial fibrillation
dabigatran
Pharmacology (medical)
rivaroxaban
Stroke
amiodarone
glomerular filtration rate
Rivaroxaban
business.industry
Atrial fibrillation
medicine.disease
RC666-701
Cardiology
Apixaban
Therapeutics. Pharmacology
Cardiology and Cardiovascular Medicine
business
medicine.drug
Kidney disease
Subjects
Details
- ISSN :
- 22253653 and 18196446
- Volume :
- 17
- Database :
- OpenAIRE
- Journal :
- Rational Pharmacotherapy in Cardiology
- Accession number :
- edsair.doi.dedup.....dd667b44950f0eb5da5deda6e2e52ab0